<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61895">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01667536</url>
  </required_header>
  <id_info>
    <org_study_id>MIP-1404-201</org_study_id>
    <nct_id>NCT01667536</nct_id>
  </id_info>
  <brief_title>A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology</brief_title>
  <official_title>A Phase 2 Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molecular Insight Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molecular Insight Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open label study of approximately 100 high-risk prostate cancer
      patients scheduled for prostatectomy and extended pelvic lymph node dissection. Patients
      receive a single IV dose of 99mTc-MIP-1404 (study drug) followed by SPECT/CT scan 3-6 hours
      after injection. As standard of care, patients will undergo prostatectomy and extended
      pelvic lymph node dissection (EPLND) within three weeks of study drug dosing. 99mTc-MIP-1404
      image data will be evaluated for visible uptake and compared with histopathology.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Ability of 99mTc-MIP-1404 to detect prostate cancer within the prostate gland.</measure>
    <time_frame>Within 3-6 hours of dosing SPECT/CT images will be taken</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tissue distribution of 99mTc-MIP-1404 SPECT/CT imaging in tumor and non-tumorous regions of the prostate and pelvic lymph nodes(as determined by histopathology) in patients undergoing standard of care prostatectomy with extended pelvic lymph node dissection.  Pathology results will be used as the truth standard for all imaging analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical safety of 99mTc-MIP-1404</measure>
    <time_frame>Vital signs will be taken at Pre-Dose and Post-Dose as well as between 3-6 hours post-dose. Lab samples: will be taken at Screening and Pre-Surgery (within 21 days of dosing)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinical laboratory tests will include hematology, clinical chemistry, and PSA.  Vital signs will include heart rate and blood pressure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ability of 99mTc-MIP-1404 to detect the extent and location of prostate cancer within the prostate gland.</measure>
    <time_frame>Within 3-6 hours of dosing SPECT/CT images will be taken</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tissue distribution of 99mTc-MIP-1404 SPECT/CT imaging in tumor and non-tumorous regions of the prostate (as determined by histopathology) in patients undergoing standard of care prostatectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability of 99mTc-MIP-1404 to detect metastatic prostate cancer within pelvic lymph nodes.</measure>
    <time_frame>Within 3-6 hours of dosing SPECT/CT images will be taken</time_frame>
    <safety_issue>No</safety_issue>
    <description>To obtain tissue distribution of 99mTc-MIP-1404 SPECT/CT imaging in tumor and non-tumorous regions of pelvic lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability of 99mTc-MIP-1404 to detect the specific location of metastatic prostate cancer within anatomic pelvic lymph node regions.</measure>
    <time_frame>Within 3-6 hours of dosing SPECT/CT images will be taken</time_frame>
    <safety_issue>No</safety_issue>
    <description>To obtain tissue distribution of 99mTc-MIP-1404 SPECT/CT imaging in tumor and non-tumorous regions of pelvic lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare performance of 99mTc-MIP-1404 against MRI for detection of prostate cancer within the prostate gland.</measure>
    <time_frame>The MRI will take place at Screening.  SPECT/CT imaging will take place within 3-6 hours of dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>To obtain MRI images (pre-dose) and 99m1404 SPECT/CT images (post-dose) for comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare performance of 99mTc-MIP-1404 against MRI for detection of metastatic prostate cancer within pelvic lymph nodes.</measure>
    <time_frame>The MRI will take place at Screening.  SPECT/CT imaging will take place within 3-6 hours of dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>To obtain MRI images (pre-dose) and 99m1404 SPECT/CT images (post-dose) for comparison.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PSMA expression relative to 99mTc-MIP-1404 imaging in a sub-set of surgical specimens.</measure>
    <time_frame>PSMA expression analysis will be conducted upon completion of enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is an exploratory objective in which PSMA staining will be conducted on a sub-set of patients' surgical specimens.  To minimize variability PSMA staining will be analyzed centrally post-enrollment completion with all specimens included to be stained at the same time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare performance of 99mTc-MIP-1404 against MRI for detection of the extent and location of prostate cancer within the prostate gland.</measure>
    <time_frame>The MRI will take place at Screening. SPECT/CT imaging will take place within 3-6 hours of dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>To obtain MRI images (pre-dose) and 99m1404 SPECT/CT images (post-dose) for comparison.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Drug: 99mTc-MIP-1404</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: 99mTc-MIP-1404</intervention_name>
    <description>A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404</description>
    <arm_group_label>Drug: 99mTc-MIP-1404</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male aged 21 years or older.

          -  Ability to provide signed informed consent and willingness to comply with protocol
             requirements.

          -  Biopsy confirmed presence of adenocarcinoma of the prostate gland.

          -  At high-risk for metastatic disease by a stage of cT3, cT4, or a total nomogram score
             of greater than or equal to 130.

          -  Scheduled to undergo radical prostatectomy with extended pelvic lymph node
             dissection.

          -  Agree to use an acceptable form of birth control for a period of 7 days after the
             99mTc MIP-1404 injection.

        Exclusion Criteria:

          -  Participating would significantly delay the scheduled standard of care therapy.

          -  Administered a radioisotope within 5 physical half lives prior to study drug
             injection.

          -  Have any medical condition or other circumstances that, in the opinion of the
             investigator, would significantly decrease obtaining reliable data, achieving study
             objectives or completing the study.

          -  Have a contraindication for MR imaging.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Scherr, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Presbyterian Hospital-Cornell</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Karnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Slawin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Vanguard Urologic Research Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Keane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edouard Trabulsi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University / Jefferson Urology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Jarrard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Ellis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judd Moul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glickman Urology &amp; Kidney Institute, Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bertram Yuh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope National Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Joniau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Briganti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vita-Salute University San Raffaele</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo Gontero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mikhail I Shkolnik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Public Institution Russian Research center for Radiology and Surgical Technologies under the Federal agency for High-tech medical care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Petr A Karlov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Petersburg State Public Medical Institution: &quot;Clinical Oncological Center&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vsevolod B Matveev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal Public State Institution &quot;Russian Oncology Research Center n.a. N.N. Blokhin under the Russian Academy of medical sciences&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Ya Alexeev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moscow Oncology Research Institute n.a. P.A. Hertsen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergey V Mishugin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City Clinical Hospital # 57</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oleg B Karyakin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Public Institution &quot;Medical Radiology Research Center&quot; of Healthcare Ministry and Social Development of Russian Federation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander K Nosov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of Oncology n.a. Professor N.N. Petrov under the Federal Agency for Healthcare and Social Development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergey B Petrov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>All-Russia Centre for Urgent Care and Radiation Medicine named after A.M. Nikiforov under the Ministry of the Russian Federation for Civil Defence, Emergencies and Elimination of Consequences of Natural Disasters</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Milan Hora, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Plzen, Department of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josef Stolz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Motol, Clinic of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladimir Student, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Olomouc, Clinic of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marek Krolupper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Na Bulovce, Department of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Pesl,, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General University Hospital in Prague, Clinic of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roman Zachoval,, MD, PhD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomayer's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcin Matuszewski, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinical Centre, Department of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henryk Zielinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Plzen, Department of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerzy Sokolowski, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Provincial Specialist Hospital in Wroclaw, Department of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tomasz Szydelko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>4th Military Teaching Hospital and Polyclinic,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geza Boszormenyi-Nagy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bajcsy-Zsilinszky Hospital, Department of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Tenke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jahn Ferenc South Pest Hospital, Department of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Istvan Buzogany, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peterfy Sandor Street Hospital, Department of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michiel Sedelaar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC St. Radboud Nijmegen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Cornell</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glickman Urology &amp; Kidney Institute, Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University / Jefferson Urology Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Vanguard Urologic Research Foundation</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc, Clinic of Urology</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Plzen, Department of Urology</name>
      <address>
        <city>Plzen</city>
        <zip>30599</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol, Clinic of Urology</name>
      <address>
        <city>Prague</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayer's Hospital</name>
      <address>
        <city>Prague</city>
        <zip>140 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Na Bulovce, Department of Urology</name>
      <address>
        <city>Prague</city>
        <zip>180 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital in Prague, Clinic of Urology</name>
      <address>
        <city>Prague</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinszky Hospital, Department of Urology</name>
      <address>
        <city>Budapest</city>
        <zip>8991</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc South Pest Hospital, Department of Urology</name>
      <address>
        <city>Budapest</city>
        <zip>H1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peterfy Sandor Street Hospital, Department of Urology</name>
      <address>
        <city>Budapest</city>
        <zip>H-1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vita-Salute University San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Turin</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre, Department of Urology</name>
      <address>
        <city>Gdansk</city>
        <zip>80952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Plzen, Department of Urology</name>
      <address>
        <city>Warsaw</city>
        <zip>00909</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Provincial Specialist Hospital in Wroclaw, Department of Urology</name>
      <address>
        <city>Wroclaw</city>
        <zip>51124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4th Military Teaching Hospital and Polyclinic,</name>
      <address>
        <city>Wroclaw</city>
        <zip>50981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Public State Institution &quot;Russian Oncology Research Center n.a. N.N. Blokhin under the Russian Academy of medical sciences&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Oncology Research Institute n.a. P.A. Hertsen</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 57</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Public Institution &quot;Medical Radiology Research Center&quot; of Healthcare Ministry and Social Development of Russian Federation</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All-Russia Centre for Urgent Care and Radiation Medicine named after A.M. Nikiforov under the Ministry of the Russian Federation for Civil Defence, Emergencies and Elimination of Consequences of Natural Disasters</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Public Medical Institution: &quot;Clinical Oncological Center&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Oncology n.a. Professor N.N. Petrov under the Federal Agency for Healthcare and Social Development</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Public Institution Russian Research center for Radiology and Surgical Technologies under the Federal agency for High-tech medical care</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <reference>
    <citation>Ahmedin J, et al. Global Cancer Statistics. CA, Cancer J Clin; 2011; 61:69-90.</citation>
  </reference>
  <reference>
    <citation>Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008 Apr;63(4):387-95. Epub 2008 Feb 4. Review.</citation>
    <PMID>18325358</PMID>
  </reference>
  <reference>
    <citation>Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B, Heston WD. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996 Sep;2(9):1445-51.</citation>
    <PMID>9816319</PMID>
  </reference>
  <reference>
    <citation>Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000 Sep 15;60(18):5237-43.</citation>
    <PMID>11016653</PMID>
  </reference>
  <reference>
    <citation>Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, Haas GP. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006 Apr;30(4):628-36.</citation>
    <PMID>16555021</PMID>
  </reference>
  <reference>
    <citation>Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998 Dec 1;83(11):2259-69. Review.</citation>
    <PMID>9840525</PMID>
  </reference>
  <reference>
    <citation>Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004 Feb 15;91(3):528-39. Review.</citation>
    <PMID>14755683</PMID>
  </reference>
  <reference>
    <citation>Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007 May;38(5):696-701. Epub 2007 Feb 22.</citation>
    <PMID>17320151</PMID>
  </reference>
  <reference>
    <citation>Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997 Jan;3(1):81-5.</citation>
    <PMID>9815541</PMID>
  </reference>
  <reference>
    <citation>Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther. 1998 Aug;286(2):1020-5.</citation>
    <PMID>9694964</PMID>
  </reference>
  <reference>
    <citation>Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995 Sep 4;62(5):552-8.</citation>
    <PMID>7665226</PMID>
  </reference>
  <reference>
    <citation>Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999 Jul 1;59(13):3192-8.</citation>
    <PMID>10397265</PMID>
  </reference>
  <reference>
    <citation>Maresca KP, Hillier SM, Femia FJ, Keith D, Barone C, Joyal JL, Zimmerman CN, Kozikowski AP, Barrett JA, Eckelman WC, Babich JW. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009 Jan 22;52(2):347-57.</citation>
    <PMID>19111054</PMID>
  </reference>
  <reference>
    <citation>Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009 Sep 1;69(17):6932-40. Epub 2009 Aug 25.</citation>
    <PMID>19706750</PMID>
  </reference>
  <reference>
    <citation>Rao JN, Scott AJ. A simple method for the analysis of clustered binary data. Biometrics. 1992 Jun;48(2):577-85.</citation>
    <PMID>1637980</PMID>
  </reference>
  <reference>
    <citation>Durkalski VL, Palesch YY, Lipsitz SR, Rust PF. Analysis of clustered matched-pair data for a non-inferiority study design. Stat Med. 2003 Jan 30;22(2):279-90.</citation>
    <PMID>12520562</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 12, 2013</lastchanged_date>
  <firstreceived_date>August 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PROSTATE CANCER</keyword>
  <keyword>HIGH-RISK</keyword>
  <keyword>PROSTATECTOMY SURGERY</keyword>
  <keyword>NEWLY DIAGNOSED</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
